See the DrugPatentWatch profile for Thalidomide
Which thalidomide analogs have patents (and who typically holds them)?
The best-known “thalidomide analog” family includes lenalidomide (Revlimid) and pomalidomide (Pomalyst). The core patents for these drugs were originally filed by the companies that developed and commercialized them, and later rights are often enforced through a mix of foundational composition-of-matter patents plus additional patent estates around specific formulations, methods of use, or process improvements.
Patent status is complex because different patents can expire at different times depending on jurisdiction and the specific right at issue (composition vs. formulation vs. method). [1][2]
When do thalidomide-analog drug patents expire?
Patent expiration depends on:
- The country (US vs EU vs Japan, etc.).
- The specific patent in the “family” (not all members expire together).
- Whether patent term adjustments, extensions, or regulatory exclusivity affect real-world market timing.
For thalidomide analogs, the broad pattern is that earlier foundational patents are older and closer to expiry, while later-life patents (for example, reformulations or specific indications) can extend enforceability until their individual deadlines. [1][2]
Can generics or biosimilars enter before the last thalidomide-analog patent expires?
Yes, in principle. Competition can appear while some patents remain in force if:
- A generic manufacturer “carves out” uses covered by remaining patents, or
- The entrant successfully challenges the remaining patents, or
- Only some listed patents are infringed (or none are found to be infringed).
In the US, this often plays out through Hatch-Waxman-style “paragraph IV” challenges that aim to invalidate or find non-infringement for specific patents. [1][3]
Why are patent disputes common with lenalidomide and pomalidomide?
Thalidomide-analog patents are frequently litigated because they cover high-value products and the market exclusivity window is tightly tied to:
- How courts interpret claims (for example, whether a generic product meets the claim elements),
- Whether claims are valid (novelty/obviousness issues),
- Whether certain indications are still protected.
That claim-by-claim structure makes patent thickets likely, which in turn drives repeated legal filings until the last enforceable right is resolved. [1][3]
What counts as “thalidomide analog” for patent searching?
When people search for “thalidomide analog patents,” they may mean:
- Direct derivatives (e.g., lenalidomide, pomalidomide),
- Broader analog classes (including “IMiDs” in general),
- Or analog-related intermediates, synthetic routes, and formulation patents.
Search strategy usually needs to cover both the drug name and chemical-family terms, plus the patent assignee/applicant names tied to development and commercialization. [2]
How to find the specific patents tied to a product name (best approach)?
Use a structured workflow:
1. Start from the marketed product (e.g., lenalidomide/Revlimid, pomalidomide/Pomalyst).
2. Look up the patent families listed for that product in major patent/patent-linking databases for the relevant country.
3. Filter by patent type (composition, method of use, formulation, process).
4. Track each patent’s scheduled expiration and any adjustments/extensions.
5. Cross-check whether there are active litigations or “stay/trigger” events that affect actual launch timing.
This kind of process is how analysts map “which patent controls market entry” rather than relying on generic statements about expiry dates. [1][2][3]
Sources
- https://patents.google.com/
- https://www.lens.org/
- https://www.fda.gov/drugs/information-consumers-and-patients-drugs/and-guidance-related-us-approval-process-terms-hatch-waxman-act